App-Quantinova.ai

2307 Abstracts

Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma

Alejandro Berkovits - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Brain metastasis

Pembrolizumab

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

Ana C. Xavier - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Aggressive NK cell leukemia

Pembrolizumab

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Matasar - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diffuse large B-cell lymphoma

Pembrolizumab

In Vitro Drug Studies of Inhibiting MDSC to Improve Efficacy of ICI (immune check point inhibitor) Therapy in Ph(-) myeloproliferative Neoplasm

Jen-Chin Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Pembrolizumab

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Alfred Chung - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Pembrolizumab

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Timothy J. Voorhees - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Pembrolizumab

Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients

Sushmitha Nanja Reddy - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Pembrolizumab

Filters

2307 Abstracts